Neurocrine Biosciences Inc. (NBIX)

$146.8

+0.7

(+0.48%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $144.83
    $147.95
    $146.80
    downward going graph

    1.34%

    Downside

    Day's Volatility :2.11%

    Upside

    0.77%

    downward going graph
  • $99.36
    $150.39
    $146.80
    downward going graph

    32.32%

    Downside

    52 Weeks Volatility :33.93%

    Upside

    2.39%

    downward going graph

Returns

PeriodNeurocrine Biosciences Inc.Sector (Health Care)Index (Russel 2000)
3 Months
7.43%
6.5%
0.0%
6 Months
2.78%
7.1%
0.0%
1 Year
45.55%
9.8%
0.0%
3 Years
52.55%
14.2%
-20.2%

Highlights

Market Capitalization
14.7B
Book Value
$23.72
Earnings Per Share (EPS)
3.67
PE Ratio
39.75
PEG Ratio
0.44
Wall Street Target Price
160.72
Profit Margin
18.65%
Operating Margin TTM
20.44%
Return On Assets TTM
10.08%
Return On Equity TTM
18.16%
Revenue TTM
2.0B
Revenue Per Share TTM
20.15
Quarterly Revenue Growth YOY
22.6%
Gross Profit TTM
1.0B
EBITDA
492.9M
Diluted Eps TTM
3.67
Quarterly Earnings Growth YOY
0.65
EPS Estimate Current Year
3.99
EPS Estimate Next Year
6.34
EPS Estimate Current Quarter
1.01
EPS Estimate Next Quarter
1.18

Analyst Recommendation

Buy
    76%Buy
    23%Hold
    0
    0%Sell
Based on 34 Wall street analysts offering stock ratings for Neurocrine Biosciences Inc.(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
25
Hold
8
9
9
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 9.48%

Current $146.80
Target $160.72

Company Financials

FY18Y/Y Change
Revenue
451.2M
↑ 179.19%
Net Income
21.1M
↓ 114.81%
Net Profit Margin
4.68%
↑ 92.87%
FY19Y/Y Change
Revenue
788.1M
↑ 74.65%
Net Income
37.0M
↑ 75.26%
Net Profit Margin
4.69%
↑ 0.01%
FY20Y/Y Change
Revenue
1.0B
↑ 32.71%
Net Income
407.3M
↑ 1000.81%
Net Profit Margin
38.94%
↑ 34.25%
FY21Y/Y Change
Revenue
1.1B
↑ 8.38%
Net Income
89.6M
↓ 78.0%
Net Profit Margin
7.9%
↓ 31.04%
FY22Y/Y Change
Revenue
1.5B
↑ 31.34%
Net Income
154.5M
↑ 72.43%
Net Profit Margin
10.38%
↑ 2.48%
FY23Y/Y Change
Revenue
1.9B
↑ 26.76%
Net Income
249.7M
↑ 61.62%
Net Profit Margin
13.23%
↑ 2.85%
Q4 FY22Q/Q Change
Revenue
412.0M
↑ 6.21%
Net Income
89.0M
↑ 29.93%
Net Profit Margin
21.6%
↑ 3.94%
Q1 FY23Q/Q Change
Revenue
420.4M
↑ 2.04%
Net Income
-76.6M
↓ 186.07%
Net Profit Margin
-18.22%
↓ 39.82%
Q2 FY23Q/Q Change
Revenue
452.7M
↑ 7.68%
Net Income
95.5M
↓ 224.67%
Net Profit Margin
21.1%
↑ 39.32%
Q3 FY23Q/Q Change
Revenue
498.8M
↑ 10.18%
Net Income
83.1M
↓ 12.98%
Net Profit Margin
16.66%
↓ 4.44%
Q4 FY23Q/Q Change
Revenue
515.2M
↑ 3.29%
Net Income
147.7M
↑ 77.74%
Net Profit Margin
28.67%
↑ 12.01%
Q1 FY24Q/Q Change
Revenue
515.3M
↑ 0.02%
Net Income
43.4M
↓ 70.62%
Net Profit Margin
8.42%
↓ 20.25%
FY18Y/Y Change
Total Assets
993.2M
↑ 21.47%
Total Liabilities
512.4M
↑ 15.03%
FY19Y/Y Change
Total Assets
1.3B
↑ 31.5%
Total Liabilities
669.1M
↑ 30.59%
FY20Y/Y Change
Total Assets
1.7B
↑ 32.83%
Total Liabilities
608.5M
↓ 9.06%
FY21Y/Y Change
Total Assets
2.1B
↑ 19.47%
Total Liabilities
698.5M
↑ 14.79%
FY22Y/Y Change
Total Assets
2.4B
↑ 14.29%
Total Liabilities
660.9M
↓ 5.38%
FY23Y/Y Change
Total Assets
3.3B
↑ 37.27%
Total Liabilities
1.0B
↑ 54.24%
Q4 FY22Q/Q Change
Total Assets
2.4B
↑ 10.51%
Total Liabilities
660.9M
↑ 10.37%
Q1 FY23Q/Q Change
Total Assets
2.4B
↓ 0.38%
Total Liabilities
675.3M
↑ 2.18%
Q2 FY23Q/Q Change
Total Assets
2.6B
↑ 10.73%
Total Liabilities
760.1M
↑ 12.56%
Q3 FY23Q/Q Change
Total Assets
2.8B
↑ 9.0%
Total Liabilities
846.1M
↑ 11.31%
Q4 FY23Q/Q Change
Total Assets
3.3B
↑ 14.16%
Total Liabilities
1.0B
↑ 20.48%
Q1 FY24Q/Q Change
Total Assets
3.5B
↑ 6.8%
Total Liabilities
1.1B
↑ 6.56%
FY18Y/Y Change
Operating Cash Flow
101.4M
↓ 207.46%
Investing Cash Flow
-242.9M
↓ 3.17%
Financing Cash Flow
29.5M
↓ 94.28%
FY19Y/Y Change
Operating Cash Flow
152.1M
↑ 50.01%
Investing Cash Flow
-211.1M
↓ 13.11%
Financing Cash Flow
27.3M
↓ 7.51%
FY20Y/Y Change
Operating Cash Flow
228.5M
↑ 50.28%
Investing Cash Flow
4.1M
↓ 101.94%
Financing Cash Flow
-157.8M
↓ 677.75%
FY21Y/Y Change
Operating Cash Flow
256.5M
↑ 12.25%
Investing Cash Flow
-130.2M
↓ 3275.61%
Financing Cash Flow
27.4M
↓ 117.36%
FY22Y/Y Change
Operating Cash Flow
339.4M
↑ 32.32%
Investing Cash Flow
-177.1M
↑ 36.02%
Financing Cash Flow
-234.3M
↓ 955.11%
Q4 FY22Q/Q Change
Operating Cash Flow
143.0M
↑ 44.74%
Investing Cash Flow
-115.6M
↑ 88.58%
Financing Cash Flow
24.6M
↑ 115.79%
Q1 FY23Q/Q Change
Operating Cash Flow
-125.2M
↓ 187.55%
Investing Cash Flow
-42.1M
↓ 63.58%
Financing Cash Flow
8.2M
↓ 66.67%
Q2 FY23Q/Q Change
Operating Cash Flow
179.6M
↓ 243.45%
Investing Cash Flow
-125.9M
↑ 199.05%
Financing Cash Flow
2.9M
↓ 64.63%

Technicals Summary

Sell

Neutral

Buy

Neurocrine Biosciences Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Neurocrine Biosciences Inc.

  • Increasing Revenue

    Revenue is up for the last 9 quarters, 310.6M → 515.29M (in $), with an average increase of 6.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 147.7M → 43.4M (in $), with an average decrease of 70.6% per quarter

Institutional Holdings

  • BlackRock Inc

    13.67%

  • Vanguard Group Inc

    9.87%

  • State Street Corporation

    3.96%

  • JPMorgan Chase & Co

    2.28%

  • Renaissance Technologies Corp

    2.24%

  • Morgan Stanley - Brokerage Accounts

    2.05%

Company Information

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

Organization
Neurocrine Biosciences Inc.
Employees
1448
CEO
Dr. Kevin C. Gorman Ph.D.
Industry
Health Technology

Discover More

FAQs